Is Nektar Therapeutics Stock a Good Investment?
Nektar Therapeutics Investment Advice | NKTR |
- Examine Nektar Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Nektar Therapeutics' leadership team and their track record. Good management can help Nektar Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Nektar Therapeutics' business and its evolving consumer preferences.
- Compare Nektar Therapeutics' performance and market position to its competitors. Analyze how Nektar Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Nektar Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Nektar Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Nektar Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Nektar Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Nektar Therapeutics Stock
Researching Nektar Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 72.0% of the company shares are owned by institutional investors. The book value of Nektar Therapeutics was now reported as 0.33. The company recorded a loss per share of 0.58. Nektar Therapeutics had not issued any dividends in recent years. The entity had 2:1 split on the 23rd of August 2000.
To determine if Nektar Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Nektar Therapeutics' research are outlined below:
| Nektar Therapeutics had very high historical volatility over the last 90 days | |
| Nektar Therapeutics has some characteristics of a very speculative penny stock | |
| Nektar Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 98.43 M. Net Loss for the year was (118.96 M) with profit before overhead, payroll, taxes, and interest of 67.74 M. | |
| Nektar Therapeutics currently holds about 546.39 M in cash with (175.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 72.0% of the company shares are owned by institutional investors |
Nektar Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Nektar Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Nektar Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Nektar Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 160.74 M.Nektar Therapeutics' profitablity analysis
The company has Profit Margin (PM) of (1.21) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.85) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.85.Determining Nektar Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Nektar Therapeutics is a good buy. For example, gross profit margin measures Nektar Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Nektar Therapeutics' profitability and make more informed investment decisions.
Basic technical analysis of Nektar Stock
As of the 24th of March, Nektar Therapeutics secures the Mean Deviation of 3.99, risk adjusted performance of 0.0128, and Downside Deviation of 5.11. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nektar Therapeutics, as well as the relationship between them. Please verify Nektar Therapeutics coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Nektar Therapeutics is priced some-what accurately, providing market reflects its recent price of 0.86 per share. Given that Nektar Therapeutics is a hitting penny stock territory we strongly suggest to closely look at its total risk alpha.Nektar Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nektar Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nektar Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nektar Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nektar Therapeutics' Outstanding Corporate Bonds
Nektar Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nektar Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nektar bonds can be classified according to their maturity, which is the date when Nektar Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Nektar Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Nektar Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0128 | |||
| Market Risk Adjusted Performance | (0.01) | |||
| Mean Deviation | 3.99 | |||
| Semi Deviation | 4.36 | |||
| Downside Deviation | 5.11 | |||
| Coefficient Of Variation | 20432.56 | |||
| Standard Deviation | 5.69 | |||
| Variance | 32.43 | |||
| Information Ratio | 0.0095 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | 0.2482 | |||
| Sortino Ratio | 0.0106 | |||
| Treynor Ratio | (0.02) | |||
| Maximum Drawdown | 32.26 | |||
| Value At Risk | (7.89) | |||
| Potential Upside | 10.11 | |||
| Downside Variance | 26.14 | |||
| Semi Variance | 19.04 | |||
| Expected Short fall | (5.32) | |||
| Skewness | 1.21 | |||
| Kurtosis | 3.06 |
| Risk Adjusted Performance | 0.0128 | |||
| Market Risk Adjusted Performance | (0.01) | |||
| Mean Deviation | 3.99 | |||
| Semi Deviation | 4.36 | |||
| Downside Deviation | 5.11 | |||
| Coefficient Of Variation | 20432.56 | |||
| Standard Deviation | 5.69 | |||
| Variance | 32.43 | |||
| Information Ratio | 0.0095 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | 0.2482 | |||
| Sortino Ratio | 0.0106 | |||
| Treynor Ratio | (0.02) | |||
| Maximum Drawdown | 32.26 | |||
| Value At Risk | (7.89) | |||
| Potential Upside | 10.11 | |||
| Downside Variance | 26.14 | |||
| Semi Variance | 19.04 | |||
| Expected Short fall | (5.32) | |||
| Skewness | 1.21 | |||
| Kurtosis | 3.06 |
Consider Nektar Therapeutics' intraday indicators
Nektar Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Nektar Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 172344.0 | |||
| Daily Balance Of Power | (0.10) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 0.87 | |||
| Day Typical Price | 0.87 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) |
Nektar Stock media impact
Far too much social signal, news, headlines, and media speculation about Nektar Therapeutics that are available to investors today. That information is available publicly through Nektar media outlets and privately through word of mouth or via Nektar internal channels. However, regardless of the origin, that massive amount of Nektar data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Nektar Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nektar Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nektar Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nektar Therapeutics alpha.
Nektar Therapeutics Corporate Management
| Mark JD | Chief VP | Profile | |
| Mark Wilson | Chief Sec | Profile | |
| Sandra Gardiner | Interim Officer | Profile | |
| Kevin Brodbeck | VP Operations | Profile |
Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.